Martin David Harp

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Eyecyte-RPE is a suspension of human induced pluripotent stem cell–derived retinal pigment epithelial cells.

The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Each company will hold a respective special meeting of stockholders to vote on the approval of the merger.

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Recent estimates show that there are over 2 billion users on Instagram, of which over 726.8 million interact with reels on the platform.

The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in patients with open-angle glaucoma.

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief.

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal endothelial disease.

Administered via intravitreal injection, Synthopsin-MCO-010 possesses a promoter to specifically target ON-bipolar cells.

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

The acquisition also includes the ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software technology and LENSAR legacy laser system.

The trial evaluated sozinibercept (2 mg) every 4 or 8 weeks in combination with aflibercept (2 mg), as per label, every 8 weeks after a loading phase for the treatment of wet AMD.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact.

The 9 recipients receive $55,000 in seed money for collaborative projects that target one or more of the foundation’s strategic research goals.

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 of its ongoing phase 1 clinical trial of TH103 in treatment-naïve nAMD patients in the second half of 2025.